Sector News

Pfizer to shutter two UK sites

November 10, 2016
Life sciences

Drugs giant Pfizer has announced plans to close two of its three key UK supply sites, but insists the decision has nothing to do with Brexit.

According to media reports, the firm’s manufacturing site in Park Royal, London, as well as its global cold chain packaging and distribution facility in Portsmouth will be closed in 2017 and 2020 respectively, with around 370 job losses in total.

“This review process has been going on since 2010 and the team just felt there were more production capabilities at the site in Belgium to support future demand and to ensure we can support the supply chain,” explained a spokesman for the firm, as reported by The Telegraph.

“The UK has a tricky commercial environment and doesn’t always link life sciences investment to the way patients use medicines, but this decision is not linked to Brexit or medicines access”.

Pfizer sold its flagship UK facilities in Sandwich, Kent, back in 2012, but around 700 of its employees remain employed at the Discovery Park science and business hub which is now housed there, and it still currently employs around 2,700 people at sites across the country.

By Selina McKee

Source: Pharma Times

comments closed

Related News

November 28, 2021

Founder-led biotech is making space for ideas—and diverse leaders—where it didn’t exist before

Life sciences

Decades ago, the founder-led biotech was rare and considered the tougher path to follow. Now there is a trend of founder-led biotechs that have risen in prominence in recent years, going from startup to well known with lightning speed. Scientists-turned C-suite occupants know their technology inside out. They’ve got credibility both at the bench working with their research teams and in the boardrooms selling their future products.

November 28, 2021

Pfizer to become $100B behemoth next year thanks to COVID-19 drug and vaccine: analyst

Life sciences

Pfizer’s revenue could reach $101.3 billion in 2022, with major contributions coming from the company’s BioNTech-partnered COVID vaccine and an antiviral therapeutic that has shown stellar clinical data, SVB Leerink analyst Geoffrey Porges projected in a Monday note to clients.

November 28, 2021

GlaxoSmithKline takes aim at sick pay access inequities with microgrant program and new campaign

Life sciences

In a survey commissioned by GlaxoSmithKline’s consumer health division of 2,000 working people in the U.S., almost 70% admitted to clocking in while sick, often because they couldn’t afford to lose a day’s pay. Black and Latina women were 10% more likely than white women to shun taking sick time for fear of fallout from their boss, according to the company’s 2021 Temperature Check Report.

Send this to a friend